These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 15588086

  • 1. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ, Kalet BT, Koch TH.
    J Med Chem; 2004 Dec 16; 47(26):6509-18. PubMed ID: 15588086
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
    Burke PJ, Koch TH.
    J Med Chem; 2004 Feb 26; 47(5):1193-206. PubMed ID: 14971899
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
    Saha P, Fortin S, Leblanc V, Parent S, Asselin É, Bérubé G.
    Steroids; 2012 Sep 26; 77(11):1113-22. PubMed ID: 22801351
    [Abstract] [Full Text] [Related]

  • 4. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ, Fenick DJ, Koch TH.
    Chem Res Toxicol; 1999 Jul 26; 12(7):588-96. PubMed ID: 10409398
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
    Kurebayashi J, Nukatsuka M, Nagase H, Nomura T, Hirono M, Yamamoto Y, Sugimoto Y, Oka T, Sonoo H.
    Cancer Chemother Pharmacol; 2007 Mar 26; 59(4):515-25. PubMed ID: 16900372
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF.
    Cancer Res; 1984 Jan 26; 44(1):112-9. PubMed ID: 6537799
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
    Coezy E, Borgna JL, Rochefort H.
    Cancer Res; 1982 Jan 26; 42(1):317-23. PubMed ID: 7053859
    [Abstract] [Full Text] [Related]

  • 12. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.
    Bull Cancer; 1996 Oct 26; 83(10):808-15. PubMed ID: 8952630
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
    Lyman SD, Jordan VC.
    Biochem Pharmacol; 1985 Aug 01; 34(15):2795-806. PubMed ID: 4015716
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA, Avor KS, Overacre LB, Kunchandy J, Paxton TR.
    Anticancer Drug Des; 1995 Jun 01; 10(4):311-31. PubMed ID: 7786397
    [Abstract] [Full Text] [Related]

  • 16. A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.
    Vessières A, Corbet C, Heldt JM, Lories N, Jouy N, Laïos I, Leclercq G, Jaouen G, Toillon RA.
    J Inorg Biochem; 2010 May 01; 104(5):503-11. PubMed ID: 20116857
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line.
    Borras M, Jin L, Bouhoute A, Legros N, Leclercq G.
    Biochem Pharmacol; 1994 Nov 29; 48(11):2015-24. PubMed ID: 7802690
    [Abstract] [Full Text] [Related]

  • 19. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP.
    Mol Pharm; 2012 Jan 01; 9(1):176-86. PubMed ID: 22091702
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.